- Curative Biotechnology has engaged Sterling Pharmaceutical Services to manufacture clinical supply of its metformin-based ophthalmic formulation.
- The agreement supports planned Phase 1 studies in age-related macular degeneration and a K9 retinal degeneration program.
Curative Biotechnology has announced a manufacturing agreement with Sterling Pharmaceutical Services to produce clinical supply of its metformin-based topical ophthalmic formulation. The CDMO will support the company’s planned first-in-human clinical study under its Cooperative Research and Development Agreement with the National Institutes of Health.
Sterling Pharmaceutical Services, based in Dupo, Illinois, will provide formulation development and manufacturing of sterile ophthalmic drops. The product is intended for use in Curative’s clinical programs targeting degenerative eye diseases.
The manufacturing engagement will support a planned Phase 1 clinical study in dry age-related macular degeneration, as well as a K9 study targeting PDE6-associated retinal degeneration. The company stated that establishing a manufacturing pathway is a key operational step as it advances its ophthalmology platform toward clinical evaluation.
Curative is developing a metformin-based topical formulation under an exclusive worldwide license from the National Eye Institute. The program is focused on treating intermediate and late-stage age-related macular degeneration, with additional research into genetic retinal diseases.
“We are pleased to be working with an experienced manufacturing partner capable of supporting production of sterile ophthalmic formulations as we prepare for our planned human and K9 clinical studies.”
Paul Michaels, Executive Chairman of Curative Biotechnology
